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Research Article
miR-181a/b downregulation exerts a protective
action on mitochondrial disease models
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Abstract
Mitochondrial diseases (MDs) are a heterogeneous group of
devastating and often fatal disorders due to defective oxidative
phosphorylation. Despite the recent advances in mitochondrial
medicine, effective therapies are still not available for these
conditions. Here, we demonstrate that the microRNAs miR-181a
and miR-181b (miR-181a/b) regulate key genes involved in mito-
chondrial biogenesis and function and that downregulation of
these miRNAs enhances mitochondrial turnover in the retina
through the coordinated activation of mitochondrial biogenesis
and mitophagy. We thus tested the effect of miR-181a/b inacti-
vation in different animal models of MDs, such as microph-
thalmia with linear skin lesions and Leber’s hereditary optic
neuropathy. We found that miR-181a/b downregulation strongly
protects retinal neurons from cell death and significantly amelio-
rates the disease phenotype in all tested models. Altogether, our
results demonstrate that miR-181a/b regulate mitochondrial
homeostasis and that these miRNAs may be effective gene-inde-
pendent therapeutic targets for MDs characterized by neuronal
degeneration.
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Introduction
Mitochondrial diseases (MDs) represent a relevant group of inher-
ited disorders with a cumulative prevalence of about 1:5,000 indi-
viduals (Gorman et al, 2015). They are caused by mutations in
either nuclear or mitochondrial genes resulting in oxidative phos-
phorylation (OXPHOS) impairment, leading to huge variability of
symptoms, organ involvement, and clinical course. The clinical
manifestations range from dysfunction of single tissue/structures
such as the optic nerve in Leber’s hereditary optic neuropathy
(LHON, MIM535000), to syndromic multi-organ conditions with a
prominent involvement of the central nervous system (CNS), such
as microphthalmia with linear skin lesions (MLS, MIM309801,
300887, 300952) and Leigh syndrome (LS, MIM256000). Neurons
are particularly sensitive to mitochondrial dysfunction due to their
highest energy demands, and defects in mitochondrial metabolism
may lead to severe energy deficiency, increased reactive oxygen
species (ROS), and neuronal death.
MDs are biochemically and genetically heterogeneous, and their
complexity has so far prevented the development of effective treat-
ments (Sanchez et al, 2016). In the past few years, specific
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modulation of either mitochondrial biogenesis/dynamics or mito-
chondrial clearance/quality control has been tested as possible ther-
apeutic strategies in different MD models (Viscomi et al, 2011;
Johnson et al, 2013; Cerutti et al, 2014; Civiletto et al, 2015, 2018).
In spite of initial promising data, the latter approaches failed to be
effective across different MD models [reviewed in Lightowlers et al
(2015); Viscomi et al (2015)]. We hypothesize that a synergic and
fine modulation of mitochondrial biogenesis and clearance path-
ways is necessary to ensure a more efficient neuroprotective effect.
MicroRNAs (miRNAs) are fundamental fine regulators of gene
expression and represent promising therapeutic tools due to their
capability of simultaneously modulating multiple molecular path-
ways involved in disease pathogenesis and progression. Modulation
of miRNAs has been applied, with therapeutic purposes, to different
disorders and has reached preclinical and clinical stages in specific
instances (Broderick & Zamore, 2011; Janssen et al, 2013; Ling et al,
2013; Christopher et al, 2016). miRNAs play a key role in neuron
survival, and accumulating evidence indicates that alterations of
miRNA-regulated gene networks increase the risk of neurodegenera-
tive disorders (Hebert & De Strooper, 2009). miR-181a and miR-
181b (miR-181a/b) belong to a family of miRNAs highly expressed
in different regions of brain and retina (Boudreau et al, 2014; Karali
et al, 2016) and were recently reported to target genes involved in
mitochondrial-dependent cell death (Ouyang et al, 2012; Hutchison
et al, 2013; Rodriguez-Ortiz et al, 2014) and autophagy (He et al,
2013; Tekirdag et al, 2013; Cheng et al, 2016).
Here, we show that miR-181a/b are involved in global regulation
of mitochondrial function by controlling a group of genes involved
in mitochondrial biogenesis and function, and redox balance. We
demonstrate that downregulation of these two miRNAs protects reti-
nal neurons from mitochondrial dysfunction, and ameliorates the
phenotype of three different MD animal models with ocular involve-
ment, indicating that miR-181a/b could be new therapeutic targets
for MDs.
Results
miR-181a/b control mitochondrial turnover
Bioinformatic search (Gennarino et al, 2012) allowed us to identify
PPARGC1A and NRF1, master regulators of mitochondrial biogenesis
(Wu et al, 1999; Finck & Kelly, 2006), COX11 and COQ10B, involved
in mitochondrial respiratory chain (MRC) assembly (Carr et al,
2002; Desbats et al, 2015), and PRDX3, an important mitochondrial
ROS scavenger (Wonsey et al, 2002), as putative miR-181a/b target
genes. Interestingly, quantitative real-time PCR (qPCR) analysis
indicated increased levels of all of the above-mentioned transcripts
in SH-SY5Y human neuroblastoma cells following miR-181a/b
silencing (Fig 1A). To validate the newly predicted miR-181a/b
targets, 30-UTRs of each human gene (PPARGC1A, NRF1, COX11,
COQ10B, and PRDX3), including the predicted miR-181 target site,
were cloned in the pGL3-TK-luciferase plasmid, downstream the
coding region of the luciferase reporter gene. We then tested the
ability of transfected mimic-miR-181 to affect luciferase activity. The
presence of the 30-UTR sequence of the analyzed genes inhibited
luciferase activity in response to mimic-miR-181 (Fig 1B). In addi-
tion, point mutations in the miR-181a/b binding site in the 30-UTR
of each gene abolished luciferase repression, demonstrating that
these miRNAs directly and specifically target NRF1, COX11,
COQ10B, and PRDX3 (Fig 1B). Direct targeting of PPARGC1A was
not validated (Fig 1B), indicating that the upregulation observed by
qPCR after miR-181a/b silencing (Fig 1A) could be the result of an
indirect effect.
Based on the above results, we reasoned that the downregula-
tion of miR-181a/b could stimulate mitochondrial biogenesis and
decided to test this hypothesis in vivo. In mammals, miR-181a
and miR-181b are organized in two clusters, namely miR-181a/b-1
and miR-181a/b-2, which are localized to different genomic loci.
The mature forms of miR-181a-1 and miR-181a-2, as well as those
of miR-181b-1 and miR-181b-2, display identical sequences.
Furthermore, both miR-181a and miR-181b contain the same
“seed” sequence (Ji et al, 2009), i.e., the region that is believed
to play the most important role in target recognition (Bartel,
2009). We chose to analyze a mouse model harboring a targeted
deletion of the miR-181a/b-1 cluster (Henao-Mejia et al, 2013).
This cluster accounts for most of the expression of mature miR-
181a/b in the retina, as demonstrated by RNA in situ hybridiza-
tion, TaqMan assays, and the increase in several previously vali-
dated miR-181a/b targets, such as Bcl2, Mcl1, Atg5, Erk2, and
Park2 (Ouyang et al, 2012; He et al, 2013; Hutchison et al, 2013;
Tekirdag et al, 2013; Rodriguez-Ortiz et al, 2014; Cheng et al,
2016) (Appendix Fig S1, Fig EV1A).
Interestingly, by qPCR, we observed increased expression levels
of Nrf1, Cox11, Coq10b Prdx3, and Ppargc1a in the eye of miR-181a/
b-1/ mice (Fig 1C). Upregulation of Nrf1 and Ppargc1a indicates
enhanced mitochondrial biogenesis (Wu et al, 1999; Finck & Kelly,
2006). In line with this observation, we detected an increase of
mitochondrial DNA (mtDNA), as measured by qPCR (Fig 1D), and
of the protein levels of MRC complex subunits (Ndufb11 and
CoxIV), mitochondrial matrix (citrate synthase [Cs]), and mitochon-
drial membranes (Mfn2 and Tim23), as assessed by Western blot
(WB) analysis in the eye of miR-181a/b-1/ mice (Fig 1E). Overall,
these data demonstrate that miR-181a/b inactivation stimulates
mitochondrial biogenesis in the CNS.
It was previously reported that miR-181a/b regulate in vitro the
expression of Atg5 and Park2, which are key players in autophagy
and mitophagy (Tekirdag et al, 2013; Cheng et al, 2016). Therefore,
we investigated whether miR-181a/b inactivation enhances mito-
phagy in the mouse eye. First, we observed, by qPCR assays, that
the transcript levels of the Atg5 and Park2 genes were upregulated
in miR-181a/b-1/ eyes (Fig EV1A). Moreover, we demonstrated,
by WB, enhanced recruitment of Park2/Parkin and of the autop-
hagic adaptor Sqstm1/p62 in mitochondrial fractions (Fig 1F), indi-
cating an increase of mitophagy in miR-181a/b-1/ eyes. We also
analyzed general autophagy by evaluating the levels of Sqstm1/p62
and of the autophagic marker Map1lc3b/Lc3-II in total protein
extracts. By WB, we observed decreased levels of these two
proteins, which is more evident in starved conditions (Fig EV1B),
without changes in the corresponding transcript levels (Fig EV1C),
indicating an increase in the autophagic flux rate in miR-181a/
b-1/ eyes.
Taken together, these results uncover an important role of
miR-181a/b in the regulation of mitochondrial turnover through
the coordination of mitochondrial biogenesis and clearance
in vivo.
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miR-181a/b inhibition protects neurons from cell death and
ameliorates the phenotype of in vivo models of MLS syndrome
Increased mitochondrial biogenesis and clearance were previously
shown to exert protective effects in mitochondrial dysfunction
(Viscomi et al, 2011; Johnson et al, 2013; Cerutti et al, 2014;
Civiletto et al, 2015, 2018). We therefore decided to verify
whether miR-181a/b inactivation could protect cells from mito-
chondrial damage. First, we verified whether miR-181a/b down-
regulation protects SH-SY5Y neuron-like cells from FCCP, a
potent OXPHOS uncoupler. In control cells, 6 hours (h) of FCCP
treatment induced a significant increase in the extent of cell
death. Interestingly, miR-181a/b-silenced cells did not display any
differences in cell death after FCCP treatment (Fig 1G), indicating
that miR-181a/b silencing protects cells from mitochondrial
damage.
Based on the above results, we decided to evaluate the neuro-
protective effect of miR-181a/b inactivation in in vivo models of
MDs. Toward this goal, we examined the consequences of miR-
181a/b downregulation in two fish models for a rare inherited
form of MD, the MLS syndrome. MLS is a neurodevelopmental
disorder characterized by microphthalmia, brain abnormalities,
and skin defects in heterozygous females and in utero lethality in
hemizygous males (Indrieri & Franco, 2016). The disease is due
to mutations in key players of the MRC, such as the holocy-
tochrome c-type synthase (HCCS), involved in complex III func-
tion (Bernard et al, 2003; Wimplinger et al, 2006; Indrieri et al,
2013), and COX7B, the 7B subunit of cytochrome c oxidase (MRC
complex IV) (Indrieri et al, 2012). We previously generated two
medakafish (Oryzias latipes) models of MLS by knocking down,
using a Morpholino(MO)-based approach, hccs or cox7B expres-
sion (Indrieri et al, 2012, 2013). Both models (hccs-MO and
A
E
F
G
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Figure 1. miR-181a/b silencing increases mitochondrial biogenesis and mitophagy and protects retinal neurons from FCCP-induced cell death.
A qPCR reveals that miR-181a/b silencing leads to upregulation of miR-181a/b predicted targets in SH-SY5Y cells. N = 3 independent experiments.
B miR-181-mimic transfection specifically inhibits luciferase activity of constructs containing WT 30-UTR predicted target sequences. Point mutations (mut) in miR-
181a/b binding sites abolish luciferase repression in all cases apart from PPARGC1A. Data are normalized to negative mimic transfection (dashed line). N = 6
independent experiments.
C qPCR reveals upregulation of miR-181a/b targets in the eyes of miR-181a/b-1/ versus miR-181a/b-1+/+ animals. n ≥ 5 animals/genotype.
D miR-181a/b-1/ mice show increased mtDNA content versus miR-181a/b-1+/+ mice as measured by qPCR. N = 4 animals/genotype.
E WB analysis (left panel) reveals increased levels of mitochondrial proteins in the eyes of miR-181a/b-1/ (-/-) versus miR-181a/b-1+/+ (+/+) mice (quantified in the
right panel). Data are normalized to either p115 or Gapdh. N ≥ 3 animals/genotype. Please note that all compared bands from +/+ and / samples are from the
same blots, which were cropped and shown split for the sake of data presentation clarity.
F WB analysis on mitochondrial and cytosolic fractions (left panel) shows increased levels of p62 and Parkin in mitochondrial fraction from the eye of / versus +/+
mice (quantified in the right panel). Data are normalized to Ndufb8 or Gapdh for mitochondrial and cytosolic fractions, respectively. N = 3 animals/genotype.
G Cell death analysis shows that miR-181a/b silencing protects SH-SY5Y cells from FCCP treatment. N ≥ 7 independent experiments.
Data information: P-values were calculated by one-tailed Student’s t-test in (A–C, E and F), by two-tailed Student’s t-test in (D), and by two-way ANOVA with post hoc
Tukey’s analysis in (G); error bars are SEM.
Source data are available online for this figure.
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cox7B-MO) showed a severe microphthalmic and microcephalic
phenotype due to increased cell death in the CNS (Indrieri et al,
2012, 2013, 2016). In medaka, the mature forms of miR-181a and
miR-181b are perfectly conserved with respect to their mamma-
lian counterparts, in terms of both sequence identity (100%) and
pattern of expression in the retina and brain (Carrella et al,
2015). We found that MO-mediated silencing of miR-181a/b in
medaka leads to increased levels of the majority of targets
involved in mitochondrial biogenesis and function, and in autop-
hagy (Fig EV2). Interestingly, downregulation of miR-181a/b in
either of the above-mentioned MLS medaka models led to a
notable reduction of cell death in the eye and brain, as shown by
TUNEL and caspase activation assays (Fig 2A–C). Accordingly,
miR-181a/b downregulation resulted in full rescue of the disease
phenotype in about 50% of both hccs (Fig 3A–C and M) and
cox7B morphants (Fig 3G–I and N). Notably, MO-mediated silenc-
ing of miR-181a/b did not cause any obvious morphological alter-
ation in the controls (Fig EV3A and B). These data show that the
downregulation of miR-181a/b ameliorates the phenotype in both
MRC complex III and IV defective models, indicating that the
protective effect of miR-181a/b silencing is gene-independent.
Current evidence supports the protective role of autophagy and
mitophagy in MDs as well as in other neurodegenerative disorders
associated with impairment of mitochondrial functions (Lightowlers
et al, 2015; Viscomi et al, 2015; Civiletto et al, 2018). Since we
showed that miR-181a/b regulate mitophagy and autophagy in the
eye, we tested whether the latter processes are implicated in the
amelioration of the phenotype mediated by miR-181a/b downregu-
lation. For this purpose, we treated hccs-MO/miR-181a/b-MO- and
cox7B-MO/miR-181a/b-MO-injected embryos with Bafilomycin A1
(Baf-A1), a general autophagy inhibitor, at 50 nM. This concentra-
tion is able to block autophagy without inducing any obvious
morphological abnormality in control embryos (Fig EV3C and F).
Interestingly, Baf-A1 treatment abolished the protective effect of
miR-181a/b downregulation in a significant number of both hccs-
MO/miR-181a/b-MO- (Fig 3D and M) and cox7B-MO/miR-181a/b-
MO-injected embryos (Fig 3J and N), indicating that increased
autophagy/mitophagy contributes to the phenotype amelioration
observed in MLS medaka models.
Since miR-181a/b downregulation also increased the mRNA
levels of erk2, a key component of the MAPK/ERK cascade, and of
bcl2 and mcl1, members of the Bcl2 anti-apoptotic family
(Fig EV2), we also tested whether the latter two pathways were
involved in the amelioration of the MLS phenotype. Therefore, we
treated hccs-MO/miR-181a/b-MO- and cox7B-MO/miR-181a/b-MO-
injected embryos with PD98059, a selective inhibitor of the
MAPK/ERK pathway (Alessi et al, 1995), or with HA14-1, an inhi-
bitor of Bcl-2 proteins (Wang et al, 2000). PD98059 and HA14-1
were used at concentrations that did not induce any morphological
alterations in control embryos [(Carrella et al, 2015) and Fig EV3D
and E]. PD98059 treatment did not have any effect on the extent
of phenotypic rescue in neither MLS models (Fig 3E, K, M and N),
suggesting that the MAPK pathway is not primarily involved in the
protective effect exerted by miR-181a/b downregulation in the
analyzed models. On the other hand, HA14-1 significantly reduced
the extent of phenotypic rescue in hccs-MO/miR-181a/b-MO-
injected embryos, but not in cox7B-MO/miR-181a/b-MO-injected
embryos (Fig 3F and L–N).
Taken together, these data suggest that increased autophagy/
mitophagy are involved in the amelioration of the MLS phenotype
in both models, indicating a primary role for this pathway in miR-
181a/b downregulation-mediated neuronal protection. Moreover,
increased levels of bcl2 play a role in the amelioration of hccs-defec-
tive embryos only, indicating that the contribution of the Bcl2-
mediated apoptotic pathway may vary depending on the specific
mitochondrial defect.
miR-181a/b inactivation ameliorates the phenotype of a drug-
induced mouse model of LHON
To validate the efficacy of miR-181a/b inactivation in mammalian
models of MDs as well, we first exploited a drug-induced mouse
model of LHON, a non-syndromic form of mitochondrial optic
neuropathy characterized by degeneration of retinal ganglion cells
(RGCs) that leads to loss of central vision. LHON represents one
of the most frequent forms of MDs with a prevalence of 1:30,000
individual with an onset occurring between the ages of 15 and 35
(Carelli et al, 2004). Similar to other MDs, LHON is characterized
by high genetic heterogeneity being caused by mutations in multi-
ple genes (Carelli et al, 2004; Meyerson et al, 2015). In about
95% of LHON patients, mutations are located in the mitochondri-
ally encoded ND1, ND4, or ND6 genes, which encode complex I
subunits (Carelli et al, 2004; Meyerson et al, 2015). Intravitreal
injection of rotenone, an MRC complex I inhibitor, leads to the
damage of RGCs, and injected mice are considered a reliable
drug-induced LHON model (Carelli et al, 2013). In order to assess
whether the genetic inactivation of miR-181a/b exerts a protective
effect against rotenone-induced LHON, miR-181a/b-1+/+ and miR-
181a/b-1/ mice were intravitreally injected with rotenone
unilaterally. As internal controls, contralateral eyes were injected
with DMSO. As previously reported (Heitz et al, 2012), miR-181a/
b-1+/+ control mice injected with rotenone displayed a notable
reduction in the number of RGCs (Fig 4A and B). In contrast, no
difference was observed in the number of RGCs between rote-
none- and DMSO-injected retina in miR-181a/b-1/ mice, both
1 and 2 weeks after injection (Fig 4A and B). Interestingly, rote-
none-injected miR-181a/b-1/ mice also showed preserved MRC
complex I activity in RGCs, as demonstrated by the staining of
NADH dehydrogenase activity, with respect to rotenone-injected
miR-181a/b-1+/+ mice (Fig 4C). Accordingly, CoxIV immunofluo-
rescence analysis showed that miR-181a/b-1 depletion protects
mitochondrial network integrity from rotenone-induced damage
(Fig 4D). Finally, we also tested retinal function by optokinetic
response (OKR). For this analysis, miR-181a/b-1+/+ and miR-
181a/b-1/ mice were bilaterally injected with rotenone or
DMSO. Interestingly, miR-181a/b-1+/+ mice showed a severe
decrease in visual performance starting 1 week after rotenone
administration, whereas miR-181a/b-1/ mice were significantly
protected against rotenone-induced toxicity (Fig 4E). Ablation of
miR-181a/b-1 rescued visual dysfunction even 2 weeks after rote-
none injection (Fig 4E). Importantly, miR-181a/b-1 ablation did
not cause per se neither abnormalities in retinal morphology and
RGC number [as shown by immunofluorescence analysis with dif-
ferent retinal cell markers (Fig EV4A–J and M)] nor alteration of
retinal function [as assessed by electroretinogram (ERG) analysis
(Fig EV4K and L)]. Altogether, these data indicate that miR-181a/
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b silencing exerts a protective effect in a drug-induced mamma-
lian model of LHON and therefore represents a potential thera-
peutic strategy for this condition.
miR-181a/b inactivation rescues the LHON phenotype in the
Ndufs4/ mouse model
Rotenone-injected mice are considered a reliable model of LHON
(Carelli et al, 2013). However, the latter represents an acute model in
which it is difficult to dissect the mechanism by which miR-181a/b
downregulation exerts its protective function. Therefore, we decided
to exploit the Ndufs4/ mouse model (Kruse et al, 2008) to further
characterize and validate the efficacy of miR-181a/b inactivation in
mammalian models of MDs. Homozygous mutations in NDUFS4 are
responsible for one of the most severe forms of Leigh syndrome (LS),
an inherited neurodegenerative condition, characterized by poor
prognosis as patients typically die before 3 years of age. NDUFS4 is a
nuclear DNA-encoded MRC complex I subunit located in the NADH
A
B C
Figure 2. miR-181a/b inhibition counteracts cell death in MLS medakafish models.
A TUNEL assays on eye and brain sections of stage (st)30 medakafish control and MO-injected embryos reveal a decrease in the number of apoptotic cells in both
hccs-MO/miR-181a/b-MO- and cox7B-MO/miR-181a/b-MO-injected compared to hccs-MO- and cox7B-MO-injected embryos. Scale bars are 20 lm.
B TUNEL-positive cells/eye. n ≥ 5 eyes for each model.
C Caspase assays show restored levels of caspase-3 and caspase-9 activities in hccs-MO/miR-181a/b-MO- and cox7B-MO/miR-181a/b-MO-injected embryos with respect
to hccs-MO- and cox7B-MO-injected embryos. n ≥ 5 embryos for each model.
Data information: P-values were calculated by analysis of deviance for negative binomial generalized linear model in (B) and by one-way ANOVA with post hoc Tukey’s
analysis in (C); error bars are SEM.
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dehydrogenase domain of the complex, responsible for its catalytic
activity (Breuer et al, 2013; Stroud et al, 2016; Zhu et al, 2016). Mice
with homozygous Ndufs4 inactivation develop a severe encephalopa-
thy resembling LS that results in death between 50 and 60 postnatal
(P) days (Kruse et al, 2008; Breuer et al, 2013). In addition, these
mice also show a LHON phenotype characterized by RGC dysfunction
starting from P16 to P20 and leading to a detectable RGC death after
P42 (Yu et al, 2015; Song et al, 2017), which makes the Ndufs4
knockout line a good model to study the effect of miR-181a/b inacti-
vation in LHON. By crossing miR-181a/b-1/ with Ndufs4/ mice,
we obtained Ndufs4//miR-181a/b-1/ animals that we exploited
to study the effect of miR-181a/b inactivation on the retinal pheno-
type. As previously reported (Yu et al, 2015), Ndufs4/ mice
showed a significant reduction in the number of RGCs at P55, as con-
firmed by NeuN-positive cell count (Fig 5A, B and E). This reduction
was rescued in Ndufs4//miR-181a/b-1/ retinas (Fig 5C and E),
A B C D E F
G H
NM
I J K L
Figure 3. miR-181a/b downregulation ameliorates the phenotype of MLS medakafish models.
A–L Representative images of st30 medaka embryos injected with hccs-MO (B) and cox7B-MO (H) alone or co-injected with miR-181a/b-MOs (C, I). Co-injection of
miR-181a/b-MOs rescues microphthalmia and microcephaly in both hccs-MO and cox7B-MO embryos. (D–F, J–L) hccs-MO/miR-181a/b-MO- and cox7B-MO/miR-
181a/b-MO-injected embryos were treated with Baf-A1, PD98059, or HA14-1. Baf-A1 treatment counteracts the protective effect of miR-181a/b downregulation in
both hccs-MO/miR-181a/b-MO and cox7B-MO/miR-181a/b-MO embryos (D, J). PD98059 treatment does not interfere with the modulation of the MLS phenotype
mediated by miR-181a/b downregulation (E, K). HA14-1 treatment counteracts the effect of miR-181a/b downregulation in the hccs-MO/miR-181a/b-MO model
but not in the cox7B-MO/miR-181a/b-MO embryos (F, L). Scale bars are 100 lm.
M, N Percentage of embryos with or without MLS phenotype in the different conditions illustrated in (A–L) in hccs-MO (M) and cox7B-MO (N) embryos. N ≥ 300
embryos/conditions. P-values were calculated by analysis of deviance for generalized linear model; error bars are SEM.
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in which the number of NeuN-positive cells was indistinguishable
from both WT and miR-181a/b-1/ mice (Fig 5D and E). Moreover,
the OKR test showed a significant amelioration of visual acuity in
Ndufs4//miR-181a/b-1/ compared to Ndufs4/ mice (Fig 5F) at
P25, indicating a remarkable effect of miR-181a/b downregulation on
both RGC dysfunction and death. Finally, we also analyzed the ERG
response, previously reported to be altered in Ndufs4/ mice with the
absence of b-wave response (Kruse et al, 2008; Yu et al, 2015). We
observed a significant amelioration of the b-wave (both in scotopic and
in photopic ranges) in Ndufs4//miR-181a/b-1/ with respect to
Ndufs4/ mice (Fig 5G and H), indicating a significant improvement
of retinal response to light stimuli at P30. Altogether, these results indi-
cate that in the Ndufs4/ model miR-181a/b downregulation
preserves RGCs from death and ameliorates the visual function before
the miRNAs exert their activity on RGC death.
To gain insight into the molecular mechanisms underlying the
amelioration of the miR-181a/b inhibition-induced Ndufs4/ retinal
phenotype, we analyzed the expression levels of miR-181a/b targets
in Ndufs4//miR-181a/b-1/ mice and we observed a significant
increase in the Nrf1 and Park2 transcripts as compared to Ndufs4/
(Fig EV5A). As previously mentioned, Park2 and Nrf1 are important
players in the control of, respectively, mitophagy (Narendra et al,
2008) and mitochondrial biogenesis (Wu et al, 1999; Finck & Kelly,
2006), i.e., pathways that we showed to be upregulated in miR-
181a/b-1/ versus WT mice (Fig 1). We therefore hypothesized
that the activation of these pathways significantly contributes to the
phenotypic improvement observed in Ndufs4//miR-181a/b-1/
mice. Notably, the levels of Parkin and p62 were increased in mito-
chondrial fractions from Ndufs4//miR-181a/b-1/ with respect to
Ndufs4/ mice (Fig EV5C and D) indicating enhanced mitophagy
A
D E
B C
Figure 4. Inactivation of miR-181a/b protects RGCs from cell death in a rotenone-induced mouse model of LHON syndrome.
A Immunofluorescence analysis with anti-NeuN antibody in the retina of miR-181a/b-1+/+ and miR-181a/b-1/ mice intravitreally injected with rotenone or DMSO.
RGCs are preserved in miR-181a/b-1/ rotenone-injected mice with respect to controls at both one and 2 weeks after injection. Scale bars are 50 lm.
B Number of RGCs/mm (indicated as %) at 1 and 2 weeks post-injection. N = 10.
C NADH dehydrogenase histochemical reaction on retinal sections of miR-181a/b-1+/+ and miR-181a/b-1/ mice intravitreally injected with rotenone or DMSO. At
1 week post-injection, NADH dehydrogenase activity is lost in RGCs (GCL, areas within dashed lines) of miR-181a/b-1+/+ rotenone-injected eyes, while it is preserved in
those of miR-181a/b-1/ rotenone-injected eyes. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. Scale bars are 50 lm.
D Immunofluorescence analysis, with an anti-CoxIV antibody, in the retina of miR-181a/b-1+/+ and miR-181a/b-1/ mice, injected with either rotenone or DMSO,
showed preserved mitochondria in miR-181a/b-1/ rotenone-injected eyes at 1 week post-injection. Dashed boxes indicate the area of magnifications shown in right
panels. Scale bars are 10 lm.
E Graphical representation of the results of the optokinetic tracking assays reported as fold change of cycles/degree. Visual acuity is preserved in miR-181a/b-1/
rotenone-injected mice with respect to controls at both 1 and 2 weeks after injection. N = 10.
Data information: P-values were calculated by one-way ANOVA with post hoc Tukey’s analysis; error bars are SEM.
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activation in response to miR-181a/b depletion. Electron microscopy
(EM) studies showed lack of accumulation of autophagosomes/
autolysosomes containing undigested material excluding a possible
mitophagy block at the level of autophagosome recruitment or
autophagosome/lysosome fusion (Fig 6B). Moreover, consistent
with Nrf1 upregulation, we showed by EM increased number of
mitochondria at both P30 and P55 in RGCs of Ndufs4//miR-181a/
b-1/ with respect to Ndufs4/ mice (Fig 6A–C). The augmented
mitochondrial biogenesis was also confirmed by increase of mtDNA
in Ndufs4//miR-181a/b-1/ versus Ndufs4/ mice, as measured
by qPCR (Fig 6D). Interestingly, the increase in number of mitochon-
dria in RGCs of Ndufs4//miR-181a/b-1/ mice was accompanied
by a notable amelioration of their morphological structure, such as
increased number of cristae and more electron-dense matrix, with
respect to Ndufs4/ mice (Fig 6A and B). Notably, NRF1 downregu-
lation significantly abolished the miR-181a/b-mediated rescue in SH-
SY5Y cells treated with FCCP, indicating that indeed NRF1 is impli-
cated in the neuroprotective effect exerted by miR-181a/b downregu-
lation (Fig EV5B). Finally, we also analyzed the biochemical activity
of MRC complexes I, II, and IV. The latter analyses showed an
A
E
G
H
F
B C D
Figure 5. miR-181a/b depletion protects RGCs and ameliorates visual function in Ndufs4/ mice.
A–D Immunofluorescence analysis with anti-NeuN antibody in the retina of WT, Ndufs4/, Ndufs4//miR-181a/b-1/, and miR-181a/b-1/ mice. RGCs are preserved
in Ndufs4//miR-181a/b-1/ with respect to Ndufs4/ mice. Scale bars are 50lm.
E Number of RGCs/mm (%). N = 5.
F Graphical representation of the results of the optokinetic tracking assays reported as fold change of cycles/degree. Visual acuity is preserved in Ndufs4//miR-
181a/b-1/ with respect to Ndufs4/ mice. N ≥ 8.
G, H Electroretinographic analysis reveals amelioration of b-wave patterns in Ndufs4//miR-181a/b-1/ with respect to Ndufs4/mice. N ≥ 5.
Data information: P-values were calculated by one-way ANOVA with post hoc Tukey’s analysis in (E and F) and by two-way ANOVA repeated measures with post hoc
analysis in (G). P-values in (G) refer to 20 log cd.s/m2 and photopic points. P-values for the other points are reported in Appendix Table S1; error bars are SEM.
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increase in complex I and II activities, and a similar trend for
complex IV activity, normalized to the activity of the Krebs
cycle enzyme citrate synthase in the Ndufs4//miR-181a/b-1/
mice compared with the Ndufs4/ mice at P30 (Fig 6E), indicating
that miR-181a/b downregulation is partially able to counteract the
complex I biochemical defect of the MRC in the Ndufs4/mouse.
Altogether, these data indicate that miR-181a/b downregulation
exerts its protective effect mainly through the simultaneous stimula-
tion of mitophagy and mitochondrial biogenesis, which leads to
enhancement of mitochondrial turnover in the retina that ultimately
results in amelioration of the mitochondrial morphological and
biochemical phenotypes (Fig 7).
Discussion
In this report, we provide a proof of principle for the genetic inacti-
vation or downregulation of miR-181a/b exerting a protective effect
from mitochondrial-mediated neurodegeneration in both in vitro
and in vivo MD models, regardless of the underlying etiopatho-
genetic events thus highlighting these two miRNAs as potential,
gene-independent, therapeutic targets for MDs characterized by
neuronal degeneration.
We found that miR-181a/b control genes implicated in mitochon-
drial biogenesis, functionality, and antioxidant response. In particu-
lar, our data demonstrate that these miRNAs control mitochondrial
biogenesis in the retina by direct targeting of Nrf1 and, together with
the already known effect on general autophagy and mitophagy
(Ouyang et al, 2012; Tekirdag et al, 2013; Cheng et al, 2016),
uncover a fundamental role of miR-181a/b in the control of mito-
chondrial turnover in the CNS. Overall, these data point to miR-
181a/b as possible hubs in the gene pathways underlying mitochon-
drial homeostasis in both physiological and pathological conditions.
We propose that the broad and beneficial impact of miR-181a/b
downregulation on MD models relies on the ability of these two
miRNAs to simultaneously and finely modulate the above-
mentioned mitochondrial-related pathways, as opposed to more
drastic and individual modulations of each of them.
A B
C
D E
Figure 6. miR-181a/b depletion enhances mitochondrial biogenesis Ndufs4/ mice.
A–C Electron microscopy analysis shows amelioration of mitochondrial morphology and increase of mitochondrial number in Ndufs4//miR-181a/b-1/ versus
Ndufs4/ mice. Scale bars are 1 lm. The quantitative increase in mitochondria is reported in (C) as number of mitochondria/RGC, at p30 and p55. N ≥ 2 animals/
genotype.
D Ndufs4//miR-181a/b-1/ mice show increased mtDNA content versus Ndufs4/ mice as measured by qPCR. N ≥ 4 animals/genotype.
E Biochemical activity of MRC complexes I, II, and IV normalized by the percentage of citrate synthase (CS) activity in Ndufs4//miR-181a/b-1/ versus Ndufs4/
mice. N ≥ 3 animals/genotype.
Data information: P-values were calculated by two-tailed Student’s t-test; error bars are SEM.
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Increased autophagy and mitophagy have been shown to exert
protective effects in MDs and in other neurodegenerative diseases
(Decressac et al, 2013; Martinez-Vicente, 2017). Of note, Parkin is
one of the main players in the clearance of damaged mitochondria
via the autophagy pathway (Geisler et al, 2010; Vives-Bauza et al,
2010). Moreover, treatment with the mTOR inhibitor rapamycin,
which activates autophagy, significantly delayed both neurodegen-
eration progression and the fatal outcome of the Ndufs4/ mouse
(Johnson et al, 2013) and of a mouse model of complex IV defi-
ciency (Civiletto et al, 2018), although a general consensus on the
mechanisms underlying the effects of rapamycin on primary mito-
chondrial dysfunction is still lacking. Here, we show that downregu-
lation of miR-181a/b leads to increased autophagy and mitophagy
in the retina. In line with these data, inhibition of general autophagy
in both hccs/miR-181a/b-MOs- and cox7B/miR-181a/b-MOs-
injected embryos reduces the neuroprotective effect of miR-181a/b
downregulation on the MLS phenotype, indicating that increased
autophagy/mitophagy significantly contributes to the phenotypic
rescue in both models. Moreover, analysis of Ndufs4//miR-181a/
b-1/ mice shows increased mitophagy in the retina, confirming
the importance of the activation of this process in the amelioration
of MD neurodegenerative phenotypes in response to miR-181a/b
downregulation. In addition, Parkin overexpression may be benefi-
cial for neuronal cell survival by acting on other pathways such as
mitochondrial dynamics, through enhancement of proteasomal
activity (Khandelwal & Moussa, 2010; Rana et al, 2013) and tran-
scriptional control of key life/death genes such as p53 (Alves da
Costa et al, 2018).
Although the removal of dysfunctional mitochondria would limit
the risk of apoptosis, an uncontrolled activation of mitophagy with-
out an appropriate compensatory mitochondrial biogenesis may
contribute to further mitochondrial dysfunction resulting in loss of
mitochondrial mass, energetic collapse, and cell death (Zhu et al,
2013; Villanueva Paz et al, 2016). Furthermore, enhanced mito-
chondrial biogenesis could be per se protective in MDs. Variability
in mitochondrial DNA content and mitochondrial biogenesis is
indeed associated with incomplete penetrance in non-manifesting
carriers of LHON (Giordano et al, 2014), and increased biogenesis
was found to improve the phenotype of different in vitro and
in vivo MD models (Komen & Thorburn, 2014). However, some
discrepant and contradictory results obtained using compounds that
trigger mitochondrial biogenesis (including bezafibrate, resveratrol,
and AICAR) (Komen & Thorburn, 2014) clearly indicate that addi-
tional work is needed to effectively exploit modulation of mitochon-
drial biogenesis to increase mitochondrial functionality in patients.
The tight balance between mitophagy and mitochondrial biogenesis
is emerging as a critical aspect in the determination of cell viability
in diseases characterized by mitochondrial dysfunction (Zhu et al,
2013). Here, we show that miR-181a/b can simultaneously control
both processes. Concomitantly to the increased mitophagy observed
following miR-181a/b inactivation, we detected increased levels of
several mitochondrial proteins and of mtDNA, indicating enhanced
mitochondrial biogenesis. Accordingly, miR-181a/b-depleted
animals showed enhanced MRC complex I activity and preserved
mitochondrial integrity in the rotenone-induced LHON model. Inter-
estingly, consistent with the higher levels of Nrf1, the Ndufs4//
miR-181a/b-1/ model showed a significantly increased number of
mitochondria in the retina compared to Ndufs4/ mice indicating
enhanced mitochondrial biogenesis. Moreover, Ndufs4//miR-
181a/b-1/ mice show amelioration of mitochondrial morphologi-
cal structure with respect to Ndufs4/ mice. In addition, analysis
of the biochemical activity of MRC complexes showed an increase
in the activity of complex I in Ndufs4//miR-181a/b-1/
compared with Ndufs4/ mice. This increase, although significant,
is still very far from compensating the profound complex I defi-
ciency shown by the Ndufs4/ mice. However, in Ndufs4//miR-
181a/b-1/ animals, we have observed a concomitant increase in
the activity of complex II, which contributes to the amelioration of
the phenotype by increasing the electron flux through complexes III
and IV. We hypothesize that this enhancement of complex activities
is mediated by miR-181a/b action on degradation of the most
dysfunctional mitochondria and enhanced mitochondrial biogenesis
(proposed in Fig 7), which translates in higher MRC activities.
We cannot exclude that other mitochondrial-related gene path-
ways may contribute to the miR-181a/b downregulation effect. For
example, another important pathway modulated by miR-181a/b is
the mitochondrial-dependent cell death in which the Bcl-2 protein
family has a key regulatory role (Rasola & Bernardi, 2007; Tait &
Green, 2010). Although the contribution of apoptosis to the patho-
genesis of primary MDs is not univocally established, increasing the
levels of anti-apoptotic Bcl-2 proteins may represent an effective
strategy to prolong cell survival and slow down disease progression.
Notably, overexpression of the Bcl-2 family protein Bcl-xL counter-
acted increased cell death and ameliorated the phenotype of the
hccs-deficient MLS medaka model (Indrieri et al, 2013). Here, we
show that miR-181a/b inhibition leads to increased levels of Bcl-2
Figure 7. Proposed model for the mechanism of action of miR-181a/b
inactivation in MDs.
In MDs, a portion of unhealthy mitochondria is degraded by mitophagy resulting
in a decreased number of mitochondria, which is not efficiently balanced by
mitochondrial biogenesis. Inactivation of miR-181a/b leads to the simultaneous
increase in mitophagy and mitochondrial biogenesis (red arrows), inducing a
significant enhancement of mitochondrial turnover and activity and ensuring a
more efficient protection from cell death.
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family members, such as Bcl-2 and Mcl-1, and rescues the pheno-
type of both MLS models tested. Moreover, HA14-1, a potent inhi-
bitor of Bcl-2 proteins (Wang et al, 2000), significantly abolishes
miR-181a/b-mediated amelioration of the MLS phenotype in the
hccs-defective, but not in the cox7B-defective model. These data
indicate that a single pathway, e.g., mitochondrial-dependent cell
death, and its modulation, may have different effects on highly
related forms of MDs, depending on the underlying genetic defect.
In addition, our data indicate that the amelioration of the phenotype
observed in Ndufs4/ mice upon miR-181a/b downregulation
preceded the effect on RGC death which is detectable only after
P42. We showed that miR-181a/b depletion improves mitochondrial
number, morphology, and MRC complex activities and rescues the
visual function before P30, thus indicating that the beneficial effects
are mainly due to mitochondrial turnover enhancement rather than
activation of the Bcl2-mediated cell death pathway. This observa-
tion strengthens our hypothesis that the simultaneous modulation
of more than one pathway represents a more effective strategy to
treat MDs.
Nevertheless, additional efforts are necessary for the exhaustive
dissection of the molecular mechanisms underlying the remarkable
efficacy of miR-181a/b downregulation in MDs, and to evaluate its
safety. It is to be noted that miR-181a/b-1/ mice show normal
life-span (Henao-Mejia et al, 2013) and no obvious abnormalities in
the eyes (Fig EV4), which provides initial support to the safety of
the downregulation of these two miRNAs.
MDs are genetically heterogeneous disorders. Although each
individual disorder is rare, collectively the total prevalence of adult
MDs is estimated to be of approximately 1 in 4,300 representing one
of the most prevalent groups of inherited neurological diseases (Gor-
man et al, 2015). In this study, we demonstrate that downregulation
of miR-181a/b exerts a neuroprotective effect in multiple models of
MDs. Our results are of particular interest for genetically heteroge-
neous conditions, such as LHON and LS for which a gene-indepen-
dent therapeutic strategy is highly desirable. In summary, we
believe that the modulation of miR-181a/b may represent effective
gene-independent therapeutic targets for MDs characterized by
neuronal degeneration.
Materials and Methods
Cell lines
HeLa and SH-SY5Y cells were obtained from ATCC and maintained
in culture with Dulbecco’s modified Eagle’s medium (Gibco) or a
1:1 mixture of Dulbecco’s modified Eagle’s medium and Nutrient
Mixture F-12, supplemented with 10% FBS (EuroClone) and 1%
penicillin/streptomycin, respectively, as suggested by the vendor.
Animal studies
Ethical statement: All studies on fish and mice were conducted in
accordance with ARRIVE guidelines for animal research and
approved by the Italian Ministry of Health, Department of Public
Health, Animal Health, Nutrition and Food Safety, in accordance
with the law on animal experimentation (article 7; D.L. 116/92;
protocol number: 389/2015-PR and 575/2017-PR). All animal
treatments were reviewed and approved in advance by the Institu-
tional Ethics Committee at the Telethon Institute of Genetics and
Medicine (Pozzuoli, Italy).
Medakafish (O. latipes) of the cab strain were maintained in
the in-house TIGEM facility (28°C on a 14/10 h light/dark cycle).
The C57BL/6-miR-181a/b/ mice were provided by Prof.
Richard A. Flavell (Department of Immunobiology, Yale Univer-
sity School of Medicine, New Haven, Connecticut, USA). The
B6.129S4-Ndufs4+/ strain described in Kruse et al (2008) was
obtained from The Jackson Laboratory and backcrossed with WT
C57BL/6 mice. Mice (male and females, 2–8 weeks old) were
housed at the TIGEM animal facility (22°C on a 12/12-h light/
dark cycle, humidity-controlled) and kept on an ad libitum
normal diet (VRF1, Special Diet Services) and free access to tap
water.
Ndufs4+/ mice were crossed with miR-181a/b-1/ animals to
generate Ndufs4+//miR-181a/b-1+/ mice. To obtain background
homogeneity, Ndufs4+//miR-181a/b-1+/ mice were then back-
crossed with miR-181a/b-1+/+ or miR-181a/b-1/ derived from
the same littermates. Ndufs4+//miR-181a/b-1+/+ were crossed
with Ndufs4+//miR-181a/b-1+/+ mice to obtain Ndufs4//miR-
181a/b-1+/+, and Ndufs4+//miR-181a/b-1/ were crossed with
Ndufs4+//miR-181a/b-1/ to obtain Ndufs4//miR-181a/b-1/.
WT (Ndufs4+/+/miR-181a/b-1+/+) controls were age-matched and
obtained both from littermates and separate litters that were co-
housed.
Luciferase assays
Human 30-UTR sequences containing miR-181a/b predicted binding
sites were amplified by PCR and inserted in the pGL3-tk-luciferase
vector. Constructs containing mutagenized miR-181a/b binding sites
were obtained using the QuikChange Site-Directed Mutagenesis Kit
(Stratagene).
Primer sequences are reported in Appendix Table S2. Plasmids
were transfected in HeLa cells (PolyFect reagent, Qiagen). After 7 h,
cells were transfected with 100 nM of miRIDIAN negative mimic or
mimic-miR-181 (Dharmacon) using Interferin (Polyplus). After 24 h,
luciferase activities were quantified using Dual-luciferase Reporter
Assay (Promega).
RNA extractions
Tissue samples were processed in QIAzol lysis reagent (Qiagen).
Total RNA from tissue and cell samples was extracted using the
RNeasy Extraction Kit (Qiagen), according to manufacturer’s
instructions.
Quantitative real-time PCR
For qPCR experiments, cDNAs were generated using QuantiTect
Reverse Transcription Kit (Qiagen), according to manufacturer’s
instructions.
Primers for qPCRs were designed to span two different exons to
avoid genomic DNA amplification using in silico tools (www.basic.
northwestern.edu/biotools/oligocalc.html) to predict their melting
temperature (Tm) and to avoid the possibility of self-annealing or
primer dimerization. The specificity of the designed primers was
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tested in silico using the BLAT or BLAST tool in Genome Browser
(https://genome.ucsc.edu/) or Ensembl (http://www.ensembl.org/
index.html). Primers were tested as described (Bustin et al, 2009).
Primer sequences are reported in Appendix Table S3. Quan-
tification data, obtained in qPCRs on cDNAs obtained from dif-
ferent treatments, are expressed in terms of cycle thresholds (Ct).
The HPRT and GAPDH genes were used as endogenous reference
controls for experiments. The Ct values were averaged for each in-
plate technical triplicate. The averaged Ct was normalized as dif-
ference in Ct values (DCt) between the analyzed mRNAs and each
reference gene in each sample analyzed. The DCt values of each
sample were then normalized with respect to the DCt values of the
control (DDCt). The variation was reported as fold change
(2DDCt). Each plate was performed in duplicate, and all the results
are shown as means  SEM of at least three independent biologi-
cal assays.
SH-SY5Y transfections and FCCP treatment
SH-SY5Y cells were transfected with 100 nM of negative control
miRNA inhibitor and miR-181a and miR-181b inhibitors (Dharma-
con) using a lipid-based transfection reagent (DharmaFECT, Dhar-
macon). Upon 72 h of transfection, SH-SY5Y cells were treated with
25 lM FCCP. After 6 h of FCCP treatment, dead cells were stained
with trypan blue and counted with the automated cell counter
(LUNA, Logos Biosystems). For double transfection, SH-SY5Y cells
were transfected with 100 nM of negative control miRNA inhibitor
or miR-181a and miR-181b inhibitors, and with 100 nM control
siRNA or siNRF1 (Dharmacon) using Lipofectamine RNAiMAX
transfection reagent (Invitrogen). Upon 72 h of transfection, SH-
SY5Y cells were treated with 25 lM FCCP. After 6 h of FCCP treat-
ment, dead cells were stained with BOBOTM-3 Iodide (Thermo Fisher
Scientific) and counted with Operetta microplate imaging reader,
the Acapella and Columbus image data processing system, and soft-
ware (PerkinElmer).
Mature miRNA quantitative assay
For mature quantitative detection of miR-181a and miR-181b, we
used hydrolysis probes (TaqMan, Applied Biosystem). The cDNAs
for mature miRNA analysis were generated using TaqMan
MicroRNA Reverse Transcription Kit with miRNA-specific primers,
according to manufacturer’s instructions. The quantification data,
obtained in TaqMan-PCRs on TaqMan-cDNAs from different treat-
ments, are expressed in terms of cycle thresholds (Ct). A TaqMan
probe for the RNA sno234 was used as endogenous control for the
experiments. The Ct values were analyzed as described in the
“Quantitative Real-Time PCR” section. Each plate was performed in
duplicate, and all results are shown as means  SEM of three inde-
pendent biological replicates.
RNA in situ hybridization (ISH)
Mouse eyes were fixed overnight in 4% PFA, cryoprotected with
30% sucrose, and embedded in OCT. Twenty-micrometer cryosec-
tions were treated with 5 lg/ml proteinase K for 15 min. After
washes with 2 mg/ml glycine and post-fixation with 4% PFA/
0.2% glutaraldehyde, sections were prehybridized with 50%
formamide, 5× sodium saline citrate buffer (SSC) and citric acid
to pH 6.1% sodium dodecyl sulfate (SDS), 500 lg/ml yeast tRNA,
and 50 lg/ml heparin. The miRCURY detection miR-181a and
miR-181b locked nucleic acid probes (Exiqon) were used at a
final concentration of 30 nM. Probe hybridization was performed
overnight at 42°C. Hybridized sections were washed with 50%
formamide, 2 × SSC at the hybridization temperature. Sections
were blocked for 1 h in MABT (100 mM maleic acid, 150 mM
NaCl, and 0.1% Tween-20) containing 1% blocking reagent
(Roche) and 10% sheep serum and incubated with alkaline phos-
phatase (AP)-labeled anti-digoxigenin antibody (1:2,000; Roche)
in MABT/1% blocking reagent overnight at 4°C. Sections were
stained with NBT-BCIP (Roche) and photographed under a Leica
DM5000 microscope.
Quantitative mitochondrial DNA content analysis
SYBR Green qPCR was performed using primers for the MT-CO1
gene (mtDNA) and the RNaseP (nuclear gene reference), as
described (Viscomi et al, 2009). mtDNA relative copy number was
calculated from threshold cycle value (DCt), and mtDNA copy
number/cell was calculated as 2 × 2DCt to account for the two
copies of RNaseP in each nucleus.
Protein isolation and Western blotting (WB)
Tissue and cells samples for total protein extraction were homoge-
nized in RIPA buffer with Protease Inhibitor Cocktail Tablet
(Roche). Protein extract concentrations were determined using the
Bio-Rad protein assay (Bio-Rad). A total of 30 lg protein from each
sample was loaded in SDS–PAGE. Mitochondrial and cytosolic
extracts were obtained from whole eyes after lens removal, as
described (Comitato et al, 2014). Thirty micrograms of proteins
from mitochondrial and cytosolic fractions from each sample was
loaded in SDS–PAGE. For WB, gels were electroblotted onto PVDF
filters (Millipore) and sequentially immunostained with the follow-
ing primary antibodies: anti-p62 (Abnova, clone 2C11, 1:1,000);
anti-LC3B (Novus, 1:500); anti-Mfn2 (Abcam, ab56889, 1:1,000);
anti-citrate synthase (Abcam, ab9660, 1:1,000); anti-p115 (Santa
Cruz, sc-48363, 1:3,000); anti-Tim23 (Santa Cruz, sc-13298, 1:250);
anti-Ndufb11 (Proteintech, 1:1,000); anti-Ndufb8 (Abcam, Total
OXPHOS Rodent WB Antibody Cocktail ab110413, 1:250); anti-
CoxIV (Cell Signaling 4844, 1:1,000); anti-Parkin (Cell Signaling
4211, 1:500); anti-Gapdh (Santa Cruz sc-32233, 1:3,000).
Proteins of interest were detected with horseradish peroxidase-
conjugated goat anti-mouse or anti-rabbit IgG antibody (1:3,000, GE
Healthcare) visualized with the Luminata Crescendo substrate (Mil-
lipore) or the Super Signal West Femto substrate (Thermo Scien-
tific), according to manufacturer’s protocol. WB images were
acquired using the ChemiDoc-It imaging system (UVP), and band
intensity was calculated using the ImageJ software. The signals for
each protein staining were quantified and then normalized for
GAPDH, p115 or Ndufb8, CS (mitochondrial fractions) in the same
sample (internal normalization). These normalized values were
then compared to the values in the control sample. Only bands on
the same blot were compared. The average of the normalized values
from three different biological replicates is reported as the relative
fold change.
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Medakafish and morpholino
Medakafish were staged as described (Iwamatsu, 2004). Design,
specificity, and inhibitory efficiency of MOs were previously
described (Indrieri et al, 2012, 2013; Carrella et al, 2015). hccs-MO,
cox7B-MO, miR-181a-MO, and miR-181b-MOs were injected into
fertilized one-cell medaka embryos at a concentration of 0.3, 0.1,
0.075, and 0.075 mM, respectively.
TUNEL assay
Whole-mount TUNEL assay was performed on stage(st)30 medaka-
fish embryos using In Situ Cell Death Detection Kit (Roche) as
described (Indrieri et al, 2013). After staining, embryos were
embedded in a mix of BSA/Gelatine and vibratome-sectioned.
Sections were analyzed with a Leica DM-6000 microscope, and
TUNEL-positive cells were manually counted in the entire retina.
Caspase assays
Twenty embryos for sample were dechorionated at st32 and frozen
in liquid nitrogen for at least 24 h. Caspase assays were performed
on protein lysates using caspase-3/7- and caspase-9-GLO luciferase
reagent (Promega) as previously reported (Indrieri et al, 2013). The
emitted luminescence signals were normalized for the protein
concentration of each sample.
Drug treatments in medakafish
st24 embryos were dechorionated and incubated for 24 h in 50 nM
Bafilomycin A (Sigma), 25 lM PD98059 (Cell Signaling), or 6 lM
HA14-1 (Sigma). Drugs were diluted in 3% DMSO/embryo medium.
Medium was refreshed twice a day. Control embryos were grown in
3% DMSO/embryo medium.
Rotenone injections
Mice were injected intravitreally with 2 ll of rotenone (Sigma)
5 mM, as reported (Heitz et al, 2012). For histological analysis of
RGCs, one murine eye was injected with rotenone and the contralat-
eral eye with DMSO (internal control). For optokinetic tests, mice
were bilaterally injected with rotenone 5 mM or DMSO.
Optokinetic tracking
Visual acuity of rotenone-injected mice was assessed by using the
optomotor system (OptoMotry; Cerebral Mechanics) as described
(Chadderton et al, 2013).
Immunofluorescence and immunohistochemistry analysis
For immunofluorescence analysis, mouse eyes were fixed in 4%
PFA, cryoprotected with 30% sucrose, embedded in OCT, and
cryosectioned. Sections were permeabilized by boiling in sodium
citrate buffer or by incubation with 1% NP-40 for 15 min for cone-
arrestin immunostaining. The following primary antibodies were
incubated overnight: anti-Rhodopsin (Abcam, ab3267, 1:5,000);
anti-cone arrestin (Millipore, AB15282, 1:1,000); anti-Pax6
(Covance, 42-6600, 1:250); anti-GS6 (Millipore, MAB 302, 1:100);
anti-Syntaxin (Sigma, S1172, 1:100); anti-NeuN (Millipore, clone
A60, 1:400); and anti-CoxIV (Cell Signaling 4844, 1:400). Sections
were then incubated with the Alexa Fluor secondary antibodies
(1:1,000; Invitrogen). Sections were counterstained with DAPI (Vec-
tor Laboratories). RGCs stained using anti-NeuN antibody were
counted on eight different slides for each eye in the areas surround-
ing the optic nerve. Sections were photographed under a LSM710
Zeiss confocal microscopy.
Electroretinogram (ERG)
Mice were dark-reared for 3 h and anesthetized. Flash electroretino-
grams (ERGs) were evoked by 10-ms light flashes generated through
a Ganzfeld stimulator (CSO, Costruzione Strumenti Oftalmici, Flor-
ence, Italy) and registered as previously described (Surace et al,
2005; Botta et al, 2016). ERGs and b-wave thresholds were assessed
using the following protocol. Eyes were stimulated with light flashes
increasing from 5.2 to + 1.3 log cd*s/m2 (which correspond to
1 × 105.2 to 20.0 cd*s/m2) in scotopic conditions. For ERG analysis
in scotopic conditions, the responses evoked by 11 stimuli (from
5.2 to + 1.3 log cd*s/m2) with an interval of 0.6 log unit were
considered. To minimize the noise, three ERG responses were aver-
aged at each 0.6 log unit stimulus from 5.2 to 0.0 log cd*s/
m2, while one ERG response was considered for higher stimuli
(from 0.0 to +1.3 log cd*s/m2). a- and b-wave amplitudes recorded
in scotopic conditions were plotted as a function of increasing light
intensity (from 4 to + 1.3 log cd*s/m2). The photopic ERG was
recorded after the scotopic session by stimulating the eye with ten
10-ms flashes of 20.0 cd*s/m2 over a constant background illumina-
tion of 50 cd/m2.
Electron microscopy and mitochondrial count
Mice were deeply anesthetized and perfused with 1% glutaralde-
hyde and 2% PFA in 200 mM HEPES buffer, pH 7.3, through the
heart. Eyes were removed and left for 1 h in the same fixative
solution. Specimens of retina were post-fixed in 1% osmium
tetroxide, dehydrated, and embedded in epoxy resin. Retina
samples were cut on ultra-microtome Leica EM UC7 and collected
on the single-slot oval grids and analyzed with FEI electron micro-
scope. Mitochondrial number/cell was determined using FEI soft-
ware, by counting the number of mitochondria in RGCs (N ≥ 10
cells for each animal).
Mitochondrial enzymatic activity measurements
Mitochondria were isolated from the two eyes of one mouse as
described (Comitato et al, 2014). The mitochondrial pellets were
kept frozen at 80°C until the measurements were performed. Each
pellet was resuspended in washing buffer (250 mM sucrose, 20 mM
HEPES-KOH, pH 7.4, 1 mM EDTA), and one cycle of freeze (in
liquid N2) and thawing (at 37°C) was performed. The activities of
MRC complex I (NADH-CoQ1 oxidoreductase), complex II (succi-
nate-CoQ1-DCIP oxidoreductase), and complex IV (cytochrome c
oxidase) and of citrate synthase were measured spectrophotometri-
cally in a 96-well plate reader, as described (Tiranti et al, 1995;
Kirby et al, 2007).
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Statistical analysis
Sample sizes were estimated on the basis of power analysis assum-
ing significance when P < 0.05 and power ≥ 0.8, and on the basis
of our previous experience. In general, for each experiment we
used ≥ 3 animals per genotype, in order to obtain statistically suit-
able values. Animals/samples were randomly allocated in the dif-
ferent groups based on the appropriate genotype/conditions/
treatments. Data were excluded from the analysis if an animal died
during experiments. Because of the obvious clinical and morpho-
logical phenotypes of most of the animals, the study was not based
on blinding of the investigators. The number of experimental repli-
cates is indicated in each figure legend. In all experiments, signifi-
cance of differences between groups was evaluated by one-way or
two-way ANOVA with post hoc Tukey’s analysis, one-tailed or two-
tailed Student’s t-test, and analysis of deviance for generalized
linear model or analysis of deviance for negative binomial general-
ized linear model as reported in figure legends. P < 0.05 was
considered significant. Quantitative data are presented as the
mean  SEM (standard error of the mean) of at least three inde-
pendent experiments.
Expanded View for this article is available online.
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